6-K filed Jun 24, 2026 at 06:14 ET
Takeda filed its 2026 Annual Integrated Report (FY2025, ended March 31, 2026) via Form 6-K. Core Revenue declined 2.6% at CER to ¥4,505.7B ($28.3B), driven by VYVANSE loss of exclusivity, partially offset by Growth & Launch Products (+4.5% CER). Core Operating Profit fell 0.9% at CER to ¥1,172.5B. Reported Operating Profit plunged 98.2% due to a provision for AMITIZA antitrust litigation. Reported EPS was -¥97. The company guides FY2026 Core Revenue to decline low-single-digit % CER and Core Operating Profit to decline 5-8% CER, with substantial launch investments. The pipeline is the key catalyst: three assets (oveporexton, rusfertide, zasocitinib) poised for launch within 12 months, with FDA Priority Review for two.